目的　研究CYFRA2 1 1在来源于上皮细胞癌变的实体恶性肿瘤诊断、分期及预后观察的临床意义。方法　采用免疫放射分析法 (IRMA)检测正常人 35例 ,非肿瘤患者 30例、恶性肿瘤患者 5 3例的血清CYFRA2 1 1水平。结果　正常人组及非肿瘤患者组检测阳性率明显低于恶性肿瘤组 (P <0 0 0 1)。CYFRA2 1 1在来源于上皮细胞癌变的实体恶性肿瘤中均有表达 :0～Ⅰ期 3 86±0 86ng/ml,Ⅱ～Ⅲa期 2 8 33± 18 92ng/ml,Ⅲb～Ⅳ期 190 2 3± 75 94ng/ml,随病期的发展 ,血清含量差异显著 (P <0 0 1)。结论　测定血清CYFRA2 1 1的含量可做为对来源于上皮细胞癌变的实体恶性肿瘤进行诊断、分期及预后判断的一项比较客观的指标 Objective To investigate the clinical significance of CYFRA2 1 1 in the diagnosis, staging and prognosis of malignant tumors derived from epithelial cells. Methods The level of serum CYFRA2 1 1 in 35 normal subjects, 30 non-tumor patients and 53 patients with malignant tumors was detected by immuno-radiometric assay (IRMA). Results The detection rate of normal group and non-tumor group was significantly lower than that of malignant tumor group (P <0.01). The expression of CYFRA2 1 1 in solid malignant tumors derived from epithelial carcinogenesis was as follows: 3 86 ± 0 86 ng / ml in stage 0-Ⅰ, 2 8 33 ± 18 92 ng / ml in stage Ⅱ-Ⅲa, and 190 2 3 in stage Ⅲb-Ⅳ ± 75 94ng / ml, with the progression of the disease, the serum content was significantly different (P <0.01). Conclusion The determination of serum CYFRA2 1 1 content can be used as a more objective indicator of the diagnosis, staging and prognosis of solid malignant tumors derived from epithelial carcinogenesis